iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6741665
SB‐236057‐A: A Selective 5‐HT1B Receptor Inverse Agonist - PMC Skip to main content
PMC home page
CNS Drug Reviews logoLink to CNS Drug Reviews
. 2006 Jun 7;7(4):433–444. doi: 10.1111/j.1527-3458.2001.tb00209.x

SB‐236057‐A: A Selective 5‐HT1B Receptor Inverse Agonist

Claire Roberts 1,✉, Jeanette Watson 1, Gary W Price 1, Derek N Middlemiss 1
PMCID: PMC6741665  PMID: 11830759

ABSTRACT

5‐HT1B autoreceptors are involved in the control of extracellular 5‐HT levels from both the terminal and cell body regions of serotonergic neurons. In this manuscript we review the pharmacological and pharmacokinetic data available for the selective and potent 5‐HT1B receptor inverse agonist, SB‐236057‐A (1′‐ethyl‐5‐(2′‐methyl‐4′‐(5‐methyl‐1,3,4‐oxadiazolyl‐2‐yl)biphenyl‐4‐carbonyl)‐2,3,6,7‐tetrahydrospiro (furo[2,3‐f]indole‐3,4′‐piperidine) hydrochloride). SB 236057‐A has been shown to have high affinity for human 5‐HT1B receptors (pK i= 8.2) and displays 80 or more fold selectivity for the human 5‐HT1B receptor over other 5‐HT receptors and a range of additional receptors, ion channels and enzymes. In functional studies at human 5‐HT1B receptors SB‐236057‐A displayed inverse agonism (pA2= 8.9) using [35S]GTPγS binding, and silent antagonism (pA2= 9.2) using cAMP accumulation. SB‐236057‐A also acted as an antagonist at the 5‐HT terminal autoreceptor as measured by [3H]5‐HT release from electrically stimulated guinea pig and human cortical slices.

In the guinea pig, pharmacokinetic analysis demonstrated that SB‐236057‐A was bioavailable and according to in vivo pharmacodynamic assays it enters brain and has a long duration of action. Importantly no side effect liability was evident at relevant doses from anxiogenic, cardiovascular, sedative or migraine viewpoints.

In vivo microdialysis studies demonstrated that SB‐236057‐A is an antagonist in the guinea pig cortex but has no effect on extracellular 5‐HT levels per se. In contrast, SB‐236057‐A increased extracellular 5‐HT levels in the guinea pig dentate gyrus. This increase in 5‐HT release was comparable to that observed after 14 days of paroxetine administration.

SB‐236057‐A has been a useful tool in confirming that, in either guinea pigs or humans, the terminal 5‐HT autoreceptor is of the 5‐HT1B subtype. It appears that acute 5‐HT1B receptor blockade, by virtue of increased 5‐HT release in the dentate gyrus, may provide a rapidly acting antidepressant.

Keywords: 5‐HT1B receptor, 5‐HT release, Inverse agonist, SB‐236057‐A

Full Text

The Full Text of this article is available as a PDF (172.2 KB).

References

  • 1. Blier P, de Montigny C, Chaput Y. Modifications of the serotonin system by antidepressant treatments: implications for the therapeutic response in major depression. J Clin Psychopharmacol 1987;7:24S–35S. [PubMed] [Google Scholar]
  • 2. Blier P, de Montigny C, Chaput Y. A role for the serotonin system in the mechanism of action of antidepressant treatments: preclinical evidence. J Clin Psychiatry 1990;51 (Suppl 12): 14–20. [PubMed] [Google Scholar]
  • 3. Blier P, Serrano A, Scatton B. Differential responsiveness of the rat dorsal and median raphe 5‐HT systems to 5‐HT receptor agonists and pCA. Synapse 1990;5:120–133. [DOI] [PubMed] [Google Scholar]
  • 4. Buhlen M, Fink K, Boing C, Gothert M. Evidence for presynaptic location of inhibitory 5‐HT1Dα‐like autoreceptors in the guinea pig cortex. Naunyn Schmiedeberg's Arch Pharmacol 1996;353:281–289. [DOI] [PubMed] [Google Scholar]
  • 5. Cooper J, Greenslade RG, Mitchel SN. Selective 5‐HT1B receptor antagonists potentiate the effects of fluoxetine on 5‐HT release in the guinea‐pig hypothalamus In: Rollema H, Abercrombie E, Sulzer D, Zackheim J. (eds). Monitoring molecules in neuroscience, 1999;263–264. [Google Scholar]
  • 6. Davidson C, Stamford JA. Evidence that 5‐HT in rat dorsal raphe nucleus is controlled by 5‐HT1A, 5‐HT1B and 5‐HT1D autoreceptors. Br J Pharmacol 1995;114:1107–1109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Davidson C, Stamford JA. Serotonin efflux in the rat ventral lateral geniculate nucleus assessed by fast cyclic voltammetry is modulated by 5‐HT1B and 5‐HT1D autoreceptors. Neuropharmacology 1996;35:1627–1634. [DOI] [PubMed] [Google Scholar]
  • 8. Erlander MG, Lovenberg TW, Baron BM, et al. Two members of a distinct subfamily of 5‐HT receptors differentially expressed in rat brain. Proc Natl Acad Sci USA 1993;90:3452–3456. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Gardier AM, Malagie I, Trillat AC, Jacquot C, Artigas F. Role of 5‐HT1A autoreceptors in the mechanism of action of serotonergic antidepressant drugs: Recent findings from in vivo microdialysis studies. Fund Clin Pharmacol 1996;10:16–27. [DOI] [PubMed] [Google Scholar]
  • 10. Gundlah C, Hjorth S, Auerbach SB. Autoreceptor antagonists enhance the effect of the reuptake inhibitor citalopram on extracellular 5‐HT: This effect persists after repeated citalopram treatment. Neuropharmacology 1997;36:475–482. [DOI] [PubMed] [Google Scholar]
  • 11. Hagan JJ, Slade PD, Gaster L, Jeffrey P, Hatcher JP, Middlemiss DN. Stimulation of 5‐HT1B receptors cause hypothermia in the guinea pig. Eur J Pharmacol 1997;331:169–174. [DOI] [PubMed] [Google Scholar]
  • 12. Hartig PR, Hoyer D, Humphrey PPA, Martin GR. Alignment of receptor nomenclature with the human genome: classification of 5‐HT1B and 5‐HT1D receptor subtypes. TIPS 1996;17:103–105. [DOI] [PubMed] [Google Scholar]
  • 13. Hoyer D, Middlemiss DN. Species differences in the pharmacology of terminal 5‐HT autoreceptors in mammalian brain. TIPS 1988;10:130–132. [DOI] [PubMed] [Google Scholar]
  • 14. Knobelman DA, Hen R, Lucki I. The effects of fluoxetine on extracellular 5‐HT in the striatum and ventral hippocampus of 5‐HT1A and 5‐HT1B receptor knockout mice. In: Rollema H, Abercrombie E, Sulzer D, Zackheim J. (eds). Monitoring molecules in neuroscience, 1999;204–205.
  • 15. Kosofsky BE, Molliver ME. The serotonergic innervation of cerebral cortex: Different classes of axon ter minals arise from dorsal and median raphe nuclei. Synapse 1987;1:153–168. [DOI] [PubMed] [Google Scholar]
  • 16. Lefkowitz RJ, Cotecchia S, Samama P, Costa T. Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. TIPS 1993;14:303–307. [DOI] [PubMed] [Google Scholar]
  • 17. Lucas JJ, Hen R. New players in the 5‐HT receptor field: Genes and knockouts. TIPS 1995;16:246–252. [DOI] [PubMed] [Google Scholar]
  • 18. Middlemiss DN, Gothert M, Schlicker E, et al. SB‐236057, a selective 5‐HT1B receptor inverse agonist, blocks the human terminal 5‐HT autoreceptor. Eur J Pharmacol 1999;375:359–365. [DOI] [PubMed] [Google Scholar]
  • 19. Montgomery SA, Henry J, McDonald G, et al. Selective serotonin reuptake inhibitors: meta‐analysis of discontinuation rates. Int Clin Psychopharmacol 1994;9:47–53. [DOI] [PubMed] [Google Scholar]
  • 20. Oliver KR, Kinsey AM, Wainwright A, McAllister G, Sirinanthsinghji D. Localisation of 5‐HT7 and 5‐HT5A receptor immunoreactivity in the rat brain. Br Neurosci Ass Abstr 1999;15:25.08P. [Google Scholar]
  • 21. Pineyro G, de Montigny C, Weiss M, Blier P. Autoregulatory properties of dorsal raphe 5‐HT neurones: Pos sible role of electronic coupling and 5‐HT1D receptors in the rat brain. Synapse 1996;22:54–62. [DOI] [PubMed] [Google Scholar]
  • 22. Price GW, Burton MJ, Collin LJ, et al. SB‐216641 and BRL 15572 — compounds to pharmacologically discriminate 5‐HT1B and 5‐HT1D receptors. Naunyn Schmiedeberg's Arch Pharmacol 1997;356:312–320. [DOI] [PubMed] [Google Scholar]
  • 23. Roberts C, Watson J, Burton M, Price GW, Jones BJ. Functional characterisation of the 5‐HT terminal auto receptor in the guinea‐pig brain cortex. Br J Pharmacol 1996;117:384–388. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Roberts C, Price GW, Jones BJ. The role of 5‐HT1B/1D receptors in the modulation of 5‐HT levels in the frontal cortex of the conscious guinea pig. Eur J Pharmacol 1997;326:23–30. [DOI] [PubMed] [Google Scholar]
  • 25. Roberts C, Belenguer A, Middlemiss DN, Routledge C. Differential effects of 5‐HT1B/1D receptor antagonists in dorsal and median raphe innervated brain regions. Eur J Pharmacol 1998;346:175–180. [DOI] [PubMed] [Google Scholar]
  • 26. Roberts C, Hatcher P, Hagan JJ, et al. The effect of SB‐236057, a selective 5‐HT1B receptor inverse agonist, on in vivo extracellular 5‐HT levels in the freely moving guinea pig. Naunyn Schmiedeberg's Arch Pharmacol 2000;362:177–183. [DOI] [PubMed] [Google Scholar]
  • 27. Schlicker E, Fink K, Molderings GJ, et al. Effects of selective 5‐HT1B (SB‐216641) and 5‐HT1D (BRL 15572) receptor ligands on guinea pig and human 5‐HT auto‐ and heteroreceptors. Naunyn Schmiedeberg's Arch Pharmacol 1997;356:321–327. [DOI] [PubMed] [Google Scholar]
  • 28. Selkirk JV, Scott C, Ho M, et al. SB‐224289–a novel selective (human) 5‐HT1B receptor antagonist with negative intrinsic activity. Br J Pharmacol 1998;125:202–208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. Sharp T, Umbers V, Gartside SE. Effect of a selective 5‐HT reuptake inhibitor in combination with 5‐HT1A and 5‐HT1B receptor antagonists on extracellular 5‐HT in rat frontal cortex in vivo. Br J Pharmacol 1997;121:941–946. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Skingle M, Sleight AJ, Feniuk W. Effects of the 5‐HT1D receptor antagonist GR 127935 on extracellular levels of 5‐HT in the guinea‐pig frontal cortex as measured by microdialysis. Neuropharmacology 1995;34:377–382. [DOI] [PubMed] [Google Scholar]
  • 31. Starkey SJ, Skingle M. 5‐HT1D as well as 5‐HT1A autoreceptors modulate 5‐HT release in the guinea pig dorsal raphe nucleus. Neuropharmacology 1994;33:393–402. [DOI] [PubMed] [Google Scholar]
  • 32. Watson JM, Burton MJ, Price GW, Jones BJ, Middlemiss DN. GR 127935 acts as a partial agonist at recom binant human 5‐HT1Dα and HT1Dβ receptors. Eur J Pharmacol 1996;314:365–372. [DOI] [PubMed] [Google Scholar]
  • 33. Weinshank RL, Zgombick JM, Macchi M, Brancheck TA, Hartig PR. Human 5‐HT1D receptor is encoded by a subfamily of two distinct genes: 5‐HT1Dα and 5‐HT1Dβ. Proc Natl Acad Sci USA 1992;89:3630–3634. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from CNS Drug Reviews are provided here courtesy of Wiley

RESOURCES